Viagra First Quarter Sales: What Goes Up Must Come Down
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer is planning several "competitive responses" to help the erectile dysfunction agent Viagra (sildenafil) rebound from a disappointing first quarter, the company told analysts during an April 20 earnings call
You may also be interested in...
Pfizer Viagra "Value Card" Offers Buy-Six-Get-One-Free Script Deal
The card program is available to patients who either pay out of pocket for Viagra or receive partial third-party coverage. Pfizer will dedicate full print and radio ads to the Value Card and update current TV commercials.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.